Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has a price-to-earnings ratio of 15.09x that is above its average ratio. Additionally, the 36-month beta value for HRMY is 0.76. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for HRMY is 30.75M and currently, short sellers hold a 21.00% ratio of that float. The average trading volume of HRMY on April 30, 2024 was 378.47K shares.
HRMY) stock’s latest price update
Harmony Biosciences Holdings Inc (NASDAQ: HRMY)’s stock price has increased by 10.01 compared to its previous closing price of 29.25. However, the company has seen a 11.53% increase in its stock price over the last five trading sessions. PRNewsWire reported 2024-04-16 that PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets.
HRMY’s Market Performance
Harmony Biosciences Holdings Inc (HRMY) has experienced a 11.53% rise in stock performance for the past week, with a -2.52% drop in the past month, and a 1.22% rise in the past quarter. The volatility ratio for the week is 3.36%, and the volatility levels for the past 30 days are at 4.37% for HRMY. The simple moving average for the past 20 days is 7.44% for HRMY’s stock, with a 2.77% simple moving average for the past 200 days.
Analysts’ Opinion of HRMY
Many brokerage firms have already submitted their reports for HRMY stocks, with BofA Securities repeating the rating for HRMY by listing it as a “Underperform.” The predicted price for HRMY in the upcoming period, according to BofA Securities is $30 based on the research report published on January 02, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see HRMY reach a price target of $31, previously predicting the price at $40. The rating they have provided for HRMY stocks is “Sell” according to the report published on September 25th, 2023.
Berenberg gave a rating of “Buy” to HRMY, setting the target price at $59 in the report published on September 07th of the previous year.
HRMY Trading at 2.85% from the 50-Day Moving Average
After a stumble in the market that brought HRMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.05% of loss for the given period.
Volatility was left at 4.37%, however, over the last 30 days, the volatility rate increased by 3.36%, as shares sank -0.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.99% lower at present.
During the last 5 trading sessions, HRMY rose by +12.51%, which changed the moving average for the period of 200-days by -8.18% in comparison to the 20-day moving average, which settled at $29.94. In addition, Harmony Biosciences Holdings Inc saw -0.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HRMY starting from Dierks Jeffrey, who sale 11,979 shares at the price of $32.00 back on Mar 15 ’24. After this action, Dierks Jeffrey now owns 0 shares of Harmony Biosciences Holdings Inc, valued at $383,328 using the latest closing price.
Dierks Jeffrey, the CHIEF COMMERCIAL OFFICER of Harmony Biosciences Holdings Inc, sale 194 shares at $32.00 during a trade that took place back on Mar 08 ’24, which means that Dierks Jeffrey is holding 0 shares at $6,208 based on the most recent closing price.
Stock Fundamentals for HRMY
Current profitability levels for the company are sitting at:
- 0.33 for the present operating margin
- 0.79 for the gross margin
The net margin for Harmony Biosciences Holdings Inc stands at 0.22. The total capital return value is set at 0.29. Equity return is now at value 29.63, with 17.35 for asset returns.
Based on Harmony Biosciences Holdings Inc (HRMY), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at 1.09. The debt to equity ratio resting at 0.37. The interest coverage ratio of the stock is 12.28.
Currently, EBITDA for the company is 231.28 million with net debt to EBITDA at -0.62. When we switch over and look at the enterprise to sales, we see a ratio of 2.74. The receivables turnover for the company is 7.75for trailing twelve months and the total asset turnover is 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.75.
Conclusion
In conclusion, Harmony Biosciences Holdings Inc (HRMY) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
